Objective: To compare the effect of inhaled beclomethasone(BECLO), started at day 3 of life, and that of systemic dexamethasone (DEX), started between day 11- 13, on clinical variables and lung inflammation in preterm infants at risk for BPD.
Setting: Tertiary neonatal intensive care service.
Patients and Interventions: Preterm neonates with RDS, and with a birthweight less than 1200g were included into the pilot study, when they were still mechanically ventilated on day 3 of life. The patients (birthweight 826± 140 g, gestational age 26.1 ± 0.9 weeks, mean ±SD) were alternately allocated to a prophylactic treatment with inhaled BECLO (n=7), or to early DEX therapy, if clinically indicated (n=9).
Measurements: Pulmonary inflammation and permeability were assessed by analyzing the levels of interleukin-8, elastase-α1-proteinase inhibitor, free elastase activity, and albu-min in tracheal aspirate fluid. The secretory component for IgA served as reference protein.
Results: There were no differences in the concentrations of interleukin-8, elastase-α1-proteinase, and albumin between both groups during day 3 to day 10. However, on day 14 -three days following initiation of DEX treatment- concentrations of the inflammatory mediators and of albumin were markedly lower in the preterm infants treated with systemic DEX therapy when compared to infants treated with inhaled BECLO (p<0.05).
Conclusion: In contrast to systemic DEX treatment, inhaled BECLO failed to decrease pulmonary inflammation and microvascular permeability in preterm infants at risk for BPD.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Groneck, P., Goetze-Speer, B. & Speer, C. Failure of Inhaled Corticosteroids To Decrease Lung Inflammation and Pulmonary Microvascular Permeability in Preterm Infants At Risk for Bpd. Pediatr Res 42, 413 (1997). https://doi.org/10.1203/00006450-199709000-00189
Issue Date:
DOI: https://doi.org/10.1203/00006450-199709000-00189